Home » Stocks » LXRX

Lexicon Pharmaceuticals, Inc. (LXRX)

Stock Price: $4.95 USD -0.10 (-1.98%)
Updated Apr 19, 2021 2:24 PM EDT - Market open
Market Cap 728.99M
Revenue (ttm) 24.00M
Net Income (ttm) -58.57M
Shares Out 144.35M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $4.95
Previous Close $5.05
Change ($) -0.10
Change (%) -1.98%
Day's Open 5.06
Day's Range 4.86 - 5.09
Day's Volume 473,702
52-Week Range 1.03 - 9.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 hour ago - Zacks Investment Research

THE WOODLANDS, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon's executive vice president, corporate and administrati...

1 week ago - GlobeNewsWire

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Lexicon (LXRX) delivered earnings and revenue surprises of 82.14% and 15.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Conference Call and Webcast at 5:00 pm Eastern Time Conference Call and Webcast at 5:00 pm Eastern Time

1 month ago - GlobeNewsWire

On Wednesday, March 10, Lexicon Pharmaceuticals (NASDAQ:LXRX) will release its latest earnings report. Benzinga's outlook for Lexicon Pharmaceuticals is included in the following report.

1 month ago - Benzinga

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

Other stocks mentioned: ADMA, AVIR, BNTX, MRNA
2 months ago - Zacks Investment Research

Your portfolio could benefit from its group of soon-to-be-commercialized drugs.

2 months ago - The Motley Fool

With the trading day practically over, the broad markets were sliding into the weekend.

Other stocks mentioned: BIIB, DDD, DUK, F, AKBA, HOG, MTN ...
2 months ago - 24/7 Wall Street

Time will always be on the investor's side.

Other stocks mentioned: CORT, CRSP, FATE, JNCE
2 months ago - The Motley Fool

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, GBT ...
2 months ago - Seeking Alpha

Find out what led to the biotech industry's biggest gains.

Other stocks mentioned: ALDX, NCNA
3 months ago - The Motley Fool

A downgrade from an analyst might have something to do with it.

3 months ago - The Motley Fool

Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.

3 months ago - Zacks Investment Research

The FDA delivered a powerful shot of good news to the company.

3 months ago - The Motley Fool

Lexicon Pharmaceuticals (NASDAQ: LXRX) shares are trading sharply higher after the company announced it received FDA regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studi...

3 months ago - Benzinga

Lexicon Pharmaceuticals (LXRX) stock is on the rise Thursday after announcing an update from the FDA for its drug sotagliflozin. The post LXRX Stock Alert: Why Lexicon Pharmaceuticals Is Up 100%+ Today ...

3 months ago - InvestorPlace

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares jumped on Thursday morning after the company announced that it received regulatory feedback from the U.S.

3 months ago - 24/7 Wall Street

THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that...

3 months ago - GlobeNewsWire

Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.

3 months ago - Zacks Investment Research

THE WOODLANDS, Texas, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-co...

3 months ago - GlobeNewsWire

Lexicon Pharmaceuticals (LXRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

3 months ago - Zacks Investment Research

Lexicon Pharma sold LXRX stock to Weight Watchers' turn-around billionaire. Lexicon sold 15% of LXRX stock to Ray Debbane's private equity company which turned Weight Watchers around.

Other stocks mentioned: WW
3 months ago - InvestorPlace

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: ALXO, ATH, BH, GDYN, SNEX, SONA, UEPS ...
3 months ago - Benzinga

THE WOODLANDS, Texas, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclin...

4 months ago - GlobeNewsWire

More clarification seems warranted for the company's shareholder-diluting move.

4 months ago - The Motley Fool

THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain institutional i...

4 months ago - GlobeNewsWire

THE WOODLANDS, Texas, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administrati...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Lexicon Pharmaceuticals (NASDAQ: LXRX) is currently up 93.64% to a price of $3.3. Tuesday the stock has been traded at a volume of 163.00 million, about 3138.31% of its recent 30-day volume average of 5...

4 months ago - Benzinga

Lexicon Pharmaceuticals (LXRX) stock is soaring higher on Tuesday after getting an upgrade from Citi analyst Yigal Nochomovitz. The post LXRX Stock: Why Lexicon Pharmaceuticals Is Soaring Tuesday appear...

4 months ago - InvestorPlace

Lexicon Pharmaceuticals (LXRX) news for Tuesday includes LXRX stock soaring higher on results from a Phase 3 clinical trial. The post Lexicon Pharmaceuticals News: Why LXRX Stock Is Soaring 43% Today ap...

5 months ago - InvestorPlace

Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies Sotagliflozin Significantly Reduced Total Car...

5 months ago - GlobeNewsWire

THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conference:

5 months ago - GlobeNewsWire

Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Lexicon (LXRX) delivered earnings and revenue surprises of 57.78% and -94.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) rose 5.7% in pre-market trading after the company reported Q3 results.

5 months ago - Benzinga

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

5 months ago - GlobeNewsWire

Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020 Lexicon Has Reduced Its Outstanding Debt by Approximately 90% in Third Quarter 2020

6 months ago - GlobeNewsWire

Lexicon Receives $160.4 Million at Closing

7 months ago - GlobeNewsWire

THE WOODLANDS, Texas, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a P...

7 months ago - GlobeNewsWire

THE WOODLANDS, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conferences:

7 months ago - GlobeNewsWire

The second half of 2020 is well underway, and with markets recovering, one of the strongest industries leading the charge has been biotech.

Other stocks mentioned: DVAX, IBB, IMGN, VKTX, XNCR
8 months ago - 24/7 Wall Street

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Lexicon (LXRX) delivered earnings and revenue surprises of -12.28% and 5.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain

8 months ago - GlobeNewsWire

Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer Lexicon to Receive Up to $224 Million in Upfront and Mile...

8 months ago - GlobeNewsWire

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

Other stocks mentioned: BIIB, CHRS, GEN, SLRX
8 months ago - Benzinga

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and ... [Read more...]

Industry
Biotechnology
IPO Date
Apr 7, 2000
Stock Exchange
NASDAQ
Ticker Symbol
LXRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 81.82% from the latest price.

Price Target
$9.00
(81.82% upside)
Analyst Consensus: Buy